Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

EVP & CHIEF BUSINESS OFFICER

EVP & CHIEF INNOVATION OFFICER

EVP & CHIEF FINANCIAL OFFICER

EVP & CHIEF SCIENTIFIC OFFICER

CHIEF MEDICAL OFFICER

PRESIDENT AND CEO

EVP & Chief Innovation Officer

EVP & Chief Business Officer

EVP & Chief Financial Officer

President & CEO

EVP & Chief Scientific Officer

EVP & Chief Medical Officer

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barrÃƒÂ© syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and opht...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-08	Premium	bought	Premium	Premium	Premium	-
2024-02-20	Premium	sold	Premium	Premium	Premium	EVP & CHIEF BUSINESS OFFICER
2024-02-20	Premium	sold	Premium	Premium	Premium	EVP & CHIEF INNOVATION OFFICER
2024-02-20	Premium	sold	Premium	Premium	Premium	EVP & CHIEF FINANCIAL OFFICER
2024-02-16	Premium	acquired	Premium	Premium	Premium	EVP & CHIEF BUSINESS OFFICER
2024-02-16	Premium	acquired	Premium	Premium	Premium	EVP & CHIEF SCIENTIFIC OFFICER
2024-02-16	Premium	acquired	Premium	Premium	Premium	EVP & CHIEF INNOVATION OFFICER
2024-02-16	Premium	acquired	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2024-02-16	Premium	acquired	Premium	Premium	Premium	EVP & CHIEF FINANCIAL OFFICER
2024-02-12	Premium	sold	Premium	Premium	Premium	EVP & CHIEF FINANCIAL OFFICER
2024-02-12	Premium	sold	Premium	Premium	Premium	EVP & CHIEF INNOVATION OFFICER
2024-02-12	Premium	sold	Premium	Premium	Premium	EVP & CHIEF BUSINESS OFFICER
2024-02-12	Premium	sold	Premium	Premium	Premium	PRESIDENT AND CEO
2023-12-27	Premium	sold	Premium	Premium	Premium	EVP & Chief Innovation Officer
2023-12-27	Premium	acquired	Premium	Premium	Premium	EVP & Chief Innovation Officer
2023-12-26	Premium	bought	Premium	Premium	Premium	-
2023-07-11	Premium	sold	Premium	Premium	Premium	EVP & Chief Business Officer
2023-07-11	Premium	sold	Premium	Premium	Premium	EVP & Chief Financial Officer
2023-07-11	Premium	sold	Premium	Premium	Premium	EVP & Chief Innovation Officer
2023-05-25	Premium	bought	Premium	Premium	Premium	-
2023-02-16	Premium	acquired	Premium	Premium	Premium	EVP & Chief Business Officer
2023-02-16	Premium	acquired	Premium	Premium	Premium	EVP & Chief Financial Officer
2023-02-15	Premium	sold	Premium	Premium	Premium	President & CEO

ANNX - Annexon, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for ANNX